An investigational prophylactic treatment once a week provided “superior bleeding prevention” as well as normal or near normal treatment. factor viii activity in patients with hemophilia Aaccording to a recent phase 3 study. One injection of efanesoctocog alfa, a factor VIII therapy, resolved nearly all bleeding episodes (97%) in the general patient population, and weekly […]